progression or deaths (PFS)

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus nivolumab alone
relatlimab plus nivolumab vs. nivolumab alone 1 0.75 [0.62; 0.91], 1 RCT, I2=0%
unassessable degree of certainty